Compares two insulins for diabetes during pregnancy
Compares insulin glargine with NPH insulin in pregnant adults with diabetes.
Key facts
- Who runs it
- Loyola University
- Where
- Maywood, United StatesSee the site
- Trial code
- Registry title
- RCT Glargine vs NPH for Treatment of DM in Pregnancy
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 160 people, planned
- Started
- 1 Apr 2024
- Expected to end
- 1 Jan 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Insulin glargine
- insulin NPH
- Record updated
- 1 October 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with type 2 diabetes or gestational diabetes who need to start insulin. It compares two kinds of insulin, glargine and NPH.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Type 2 diabetes or gestational diabetes during pregnancy that needs insulin treatment. Insulin must be started before 34 weeks of pregnancy.
- Earlier treatment
- Insulin must not have been started before the trial. Diabetes controlled only with diet changes or tablets cannot join.
Main reasons for not taking part
- Under 18 years old
- Unable to give consent in English
- Allergy to insulin
- Type 1 diabetes
- Insulin given through an insulin pump
This trial only enrols pregnant participants. The registry sentence this rests on: Patient requiring initiation of insulin therapy for Gestational Diabetes Mellitus or Type 2 Diabetes Mellitus in pregnancy
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patient requiring initiation of insulin therapy for Gestational Diabetes Mellitus or Type 2 Diabetes Mellitus in pregnancy
- At least 18 years old
- Insulin started prior to 34 weeks gestation
- Established prenatal care by 14 weeks gestation
Who cannot take part
- Receiving insulin through an insulin pump
- Allergy to insulin
- Has diagnosis of Type 1 Diabetes Mellitus
- Those under the age of 18 years old
- Those unable to consent in english
- Controlled with only diet modification or the use of oral antihyperglycemics
Where in United States
- Loyola University Medical CenterMaywood, United StatesContact: Joana Lopes Perdigao, MDTaking people
About the trial
What the trial wants to find out
We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy. Currently, many hospitals differ among use of insulin for management of DM in pregnancy, with NPH, glargine and detemir being the most commonly used forms of basal insulin. Outside of pregnancy, NPH is rarely used with glargine and determir being the more common forms of insulin used due to their fewer episodes of hypoglycemia in these patients. Detemir has been well studied in pregnancy and found to be noninferior to NPH. Unfortunately, glargine has not been as well studied in pregnancy. Thus, with this study we want to compare glargine and NPH.
Read full original descriptionShow less
The purpose of this study is to compare two different forms of insulin (Glargine and NPH) that we regularly use to manage diabetes mellitus in pregnancy.
The 2 groups in the trial
- Insulin GlargineExisting treatment, for comparison
Insulin Glargine dosed 1-2 times daily throughout pregnancy for management of diabetes mellitus.
- Insulin NPHExisting treatment, for comparison
Insulin NPH dosed 1-2 times daily throughout pregnancy for management of diabetes mellitus.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Randomized Controlled Trial of Glargine Versus Neutral Protamine Hagedorn Insulin for the Treatment of Diabetes Mellitus in Pregnancy
- Plain-language title
- Compares two insulins for diabetes during pregnancyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 October 2024